Johnson & Johnson MedTech has received a go-ahead from the FDA to begin human clinical trials of its Ottava surgical robot, ...

With FDA approval of an investigational device exemption, J&J’s soft tissue robot moves a step closer to challenging ...

Defensive industries, like healthcare, are more attractive to income investors. That's because companies in this sector are ...

Medtronic is also developing a robotic-assisted surgery device, the Hugo system, that could prove to be an important long-term tailwind. Intuitive Surgical dominates this market, but given the ...

ISRG is way ahead in the market. Its main competitor, Medtronic’s Hugo, is yet to secure the U.S. FDA approval. Johnson & Johnson is yet to begin clinical trials for its robotic surgery platform ...

One year after unveiling a timeline for its general surgical robot, Johnson & Johnson (J&J) has submitted an investigational device exemption (IDE) to the US Food and Drug Administration (FDA) as ...

Medtronic joined the market in 2021, with a CE mark for its Hugo soft tissue system. Microbot is not far off an entry into ...

The Global Surgical Stapling Device Market is projected to be valued at US$ 3,977.40 million in 2023, with an anticipated growth trajectory reaching US$ 5,930.60 million by 2033. The market is ...